Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, based on these categorizations, leukemia can be broadly classified into four types.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market

Market overview

Total addressable market for global CLL therapeutics

Vendors in the market

PART 09: Global ALL therapeutics market

Market overview

Vendors in the market

PART 10: Global AML therapeutics market

Market overview

Vendors in the market

PART 11: Global CML therapeutics market

Market overview

Vendors in the market

PART 12: Geographical segmentation

Global leukemia therapeutics market by geography

2015-2020

Leukemia therapeutics market in Americas

Leukemia therapeutics market in EMEA

Leukemia therapeutics market in APAC

PART 13: Market drivers

Special regulatory designations for drugs

Technological advances in the monitoring of leukemia

Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges

Complicated disease prognosis

Financial and infrastructural constraints

Limitations associated with current therapeutic options

Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends

Rise in the development of combination therapies

Patient assistance programs

Focus on the identification of targets for the development

of new therapies

PART 18: Vendor landscape

Competitive scenario

Other prominent vendors

PART 19: Key vendor analysis

F. Hoffmann-La Roche

Novartis

Bristol-Myers Squibb

AbbVie

Teva Pharmaceuticals

PART 20: Appendix

List of abbreviations

PART 21: Explore Technavio